Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial - Scorecard - MDSpire
Advertisement
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
Clinical Scorecard: Evaluation of Safety and Immune Response of a Prefusion-Stabilized SARS-CoV-2 Spike Subunit Vaccine Using a Second-Generation Molecular Clamp in Adults Aged 18 to 55: Results from a Phase I Randomized, Double-Blind, Active Comparator Trial
At a Glance
Category
Detail
Condition
COVID-19 caused by SARS-CoV-2
Key Mechanisms
Prefusion stabilization of SARS-CoV-2 spike protein using a second-generation molecular clamp (MC2) platform to enhance vaccine stability and immunogenicity
Target Population
Healthy adults aged 18 to 50 years previously vaccinated with ≥3 doses of approved mRNA SARS-CoV-2 vaccines
Care Setting
Phase I clinical trial setting in Australia
Key Highlights
UQSC2 vaccine utilizing MC2 platform demonstrated safety and tolerability comparable to the approved NVX-CoV2373 vaccine.
Both vaccines elicited robust neutralizing humoral immune responses against the prototypic Wuhan strain of SARS-CoV-2.
MC2 platform avoids HIV-1 sequence interference seen in first-generation molecular clamp vaccines, supporting its use for rapid vaccine development against emerging respiratory viruses.
Guideline-Based Recommendations
Diagnosis
No specific diagnostic recommendations provided; study focused on vaccine safety and immunogenicity.
Management
Administer a single booster dose of UQSC2 vaccine formulated with MF59 adjuvant to adults previously vaccinated with mRNA COVID-19 vaccines.
Use of MC2 molecular clamp platform enables stable production of subunit vaccines with potential for rapid response to emerging viral variants.
Monitoring & Follow-up
Monitor safety and tolerability post-vaccination through day 183.
Assess humoral and cellular immunogenicity responses including neutralizing antibody titers against SARS-CoV-2 variants.
Risks
Original molecular clamp vaccine halted due to interference with HIV-1 diagnostic tests caused by HIV-1 gp41 sequence homology; MC2 redesign eliminates this risk.
No significant safety concerns reported with UQSC2 in phase I trial.
Patient & Prescribing Data
Healthy adults aged 18–50 years with prior mRNA COVID-19 vaccination
Single booster dose of UQSC2 vaccine is well tolerated and elicits neutralizing antibody responses comparable to NVX-CoV2373, supporting its potential use as a booster vaccine.
Clinical Best Practices
Use molecular clamp technology to stabilize prefusion conformation of viral fusion proteins for subunit vaccine development.
Employ MC2 platform to avoid diagnostic interference issues associated with HIV-1 sequences in vaccine design.
Conduct randomized, double-blind, active comparator-controlled trials to assess safety and immunogenicity of novel vaccines.
Include assessment of both humoral and cellular immune responses over extended follow-up periods (up to 6 months).
by Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Julia A Lackenby, Noushin Jaberolansar, Jake O’Donnell, Vivian Kienzle, Varsha Kommajosyula, Nicolas Tardiota, Jillian K Bennet, Christina L Henderson, Rhiannon L Dalrymple, Justin Goh, Kym Hoger, Marianne Gillard, Martina L Jones, Karen Hughes, Ben Hughes, James Barnes, Patrick C Reading, Charani Ranasinghe, Kanta Subbarao, Trent P Munro, Paul R Young, Daniel Watterson
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
